PMC:7558914 / 10970-11242
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
241 | 241-249 | Species | denotes | patients | Tax:9606 |
255 | 26-44 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
256 | 49-68 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
257 | 107-125 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
258 | 141-153 | Chemical | denotes | azithromycin | MESH:D017963 |
259 | 158-177 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
263 | 262-271 | Disease | denotes | pneumonia | MESH:D011014 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T20 | 262-271 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T71 | 0-272 | Sentence | denotes | Different combinations of hydroxychloroquine and lopinavir/ritonavir (7/15, 46.7%) and triple therapy with hydroxychloroquine regimen 3, and azithromycin and lopinavir/ritonavir regimen 2 (6/15, 40%) were the most recommended treatments for patients with severe pneumonia. |